The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna started hitting pharmacies. Health officials encourage annual vaccination against the coronavirus, similar to ...

Moderna, Inc.'s combination flu and COVID-19 vaccine, mRNA-1083, showed strong Phase 3 results in adults over 50. Pfizer/BioNTech's combination vaccine faced setbacks, giving Moderna a potential ...

The Food and Drug Administration approved Novavax’s new COVID-19 vaccine Friday, a week after giving Pfizer and Moderna the OK on their shots, though all drugmakers say their shots will be ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

ACCESSWIRE • 9 days ago EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.

Also Read: Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows. In early June ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even Shares of Moderna ...

Expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years. The analyst notes the COVID-19 vaccine maker pushed its ...

Moderna, the Massachusetts-based biotech company that rocketed into the global spotlight during the development of its COVID-19 vaccine, announced plans on Thursday to cut costs and refocus on ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The company also ...